top of page
Search

CSL's $11.7B Vifor buy, 2021's biggest biopharma M&A deal, hits antitrust delay



Larger mergers and acquisitions often mean more regulations. See how a recent M&A has hit a few months delay due to antitrust laws. It's a great case study to prepare for your future M&As that may occur.



0 comments

留言


bottom of page